A few weeks ago for the first time an IQCC-related paper appeared in Nature, with the publication of “Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours”, with Maricel Torrent as one of the authors. Maricel defended her PhD thesis “On the mechanisms of Transition-Metal Catalyzed Model Reactions of Industrial and Synthetic Importance: A Density Functional Study” in 1998, then moved to (among others) Emory Univ. and Merck. Right now she is senior scientist at Abbvie. Congratulations Maricel!
Note: this follows the publication in Science a few weeks ago by another former IQCC member.
L.M. Lasko, C.G. Jakob, R.P. Edalji, W. Qiu, D. Montgomery, E.L. Digiammarino, T.M. Hansen, R.M. Risi, R. Frey, V. Manaves, B. Shaw, M. Algire, P. Hessler, L.T. Lam, T. Uziel, E. Faivre, D. Ferguson, F.G. Buchanan, R.L. Martin, M. Torrent, G.G. Chiang, K. Karukurichi, J.W. Langston, B.T. Weinert, C. Choudhary, P. de Vries, J.H. Van Drie, D. McElligott, E. Kesicki, R. Marmorstein, C. Sun, P.A. Cole, S.H. Rosenberg, M.R. Michaelides, A. Lai, and K.D. Bromberg
“Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours”
Nature 2017, 550, 128-132 [abstract]